VANTAGE014_4 | R Documentation |
Kaplan-Meier digitized data from VANTAGE014, figure 4 (PMID 25800891). A reported sample size of 661 for a primary endpoint of OS/safety in lung cancer.
VANTAGE014_4
A data frame of 661 observations and 3 variables:
time | event time (in weeks) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (placebo, vorinostat) | |
Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 2015; 16: 447–56.
summary(VANTAGE014_4)
kmplot(VANTAGE014_4)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.